Jeffrey Jones, MD, MPH from the Ohio State University, Columbus, OH discusses the current thought on treating relapsed and refractory chronic lymphocytic leukemia (CLL). This is an area where one can see a tremendous revolution in CLL treatment. Treatment has moved from once being mostly chemotherapy to more specifically targeting the abnormal biology of CLL. In order to do this there needs to be a fundamental understand of CLL, specifically what drives CLL growth and survival. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark
EHA 2016: Current thought on treating chronic lymphocytic leukemia
